⏳ Fetching live dividend data...
Home › Calculator › CNTA Dividend Calculator 2026
Centessa Pharmaceuticals plc · NASDAQ
Price: $40.50 · Annual div: $38.00/share · Frequency: quarterly · Payout ratio: N/A · Ex-div: —
CNTA (Centessa Pharmaceuticals plc) has a dividend yield of 93.83%, based on an annual dividend of $38.00 per share and a price of $40.50.
At a 93.83% yield, reinvesting every payout is not a realistic long-term assumption — payouts this high rarely last and the share price usually falls as they are paid, so we don't model DRIP growth for CNTA.
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.
CNTA (Centessa Pharmaceuticals plc) has a dividend yield of 93.83%, based on an annual dividend of $38.00 per share and a price of $40.50.
$10,000 in CNTA at a 93.83% yield pays about $9,383 a year ($782 a month) before taxes. Payouts this high rarely last — don't count on this income continuing at today's rate.
At a 93.83% yield, reinvesting every payout is not a realistic long-term assumption — payouts this high rarely last and the share price usually falls as they are paid, so we don't model DRIP growth for CNTA.
Enter your starting amount, monthly contribution and time horizon in the CNTA DRIP calculator at the top of this page. It reinvests each payout into new shares at the projected price, grows the dividend at the rate you choose and shows yearly income, share count, portfolio value and yield on cost. You can switch DRIP off to compare.
CNTA's next ex-dividend date has not been announced yet. Buy before the ex-dividend date to receive the next payment.
CNTA has less than a year of dividend history in our data, so there is no dividend growth rate yet.
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open CNTA position with:
Real after-tax yield depends on where you live and how you hold CNTA.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 93.83% | 91.03% | $9,383 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 79.76% | 76.96% | $7,976 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 75.06% | 72.26% | $7,506 / yr |
| 🇬🇧 UK ISA | 0% | 93.83% | 91.03% | $9,383 / yr |
| 🇬🇧 UK Taxable | 8.75% | 85.62% | 82.82% | $8,562 / yr |
| 🇨🇦 TFSA | 0% | 93.83% | 91.03% | $9,383 / yr |
| 🇨🇦 CA Taxable | 25% | 70.37% | 67.57% | $7,037 / yr |
| 🇦🇺 Super (pension) | 15% | 79.76% | 76.96% | $7,976 / yr |
| 🇦🇺 AU Taxable | 30% | 65.68% | 62.88% | $6,568 / yr |
| 🇩🇪 DE Taxable | 26.375% | 69.08% | 66.28% | $6,908 / yr |
| 🇫🇷 FR Taxable | 30% | 65.68% | 62.88% | $6,568 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $38.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
CNTA pays quarterly — 4 times per year. Ex-div: —.
How CNTA compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for CNTA sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Sale | 2026-06-24 | 281,162 | $38.00 | $10.68M | ||
| Sale | 2026-06-24 | 149,421 | $38.00 | $5.68M | ||
| D-Return | 2026-06-24 | 5,500 | $38.00 | $209.0K | ||
| D-Return | 2026-06-24 | 221,559 | $5.84 | $1.29M | ||
| D-Return | 2026-06-24 | 166,779 | $9.42 | $1.57M | ||
| D-Return | 2026-06-24 | 100,000 | $20.00 | $2.00M | ||
| D-Return | 2026-06-24 | 160,000 | $9.53 | $1.52M | ||
| D-Return | 2026-06-24 | 100,000 | $3.85 | $385.0K | ||
| D-Return | 2026-06-24 | 170,000 | $8.01 | $1.36M | ||
| D-Return | 2026-06-24 | 175,000 | $16.90 | $2.96M |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Compare CNTA with peers: CNTA vs CGEM · CNTA vs CMPX · CNTA vs DSGN
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the CNTA dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Centessa Pharmaceuticals plc (CNTA) is currently trading at $40.50, trading near its 52-week high. The current dividend yield is 93.83% based on an annual payout of $38.00 per share.
Centessa Pharmaceuticals plc (CNTA) is a healthcare stock currently trading at $40.50 with a dividend yield of 93.83%. It pays an annual dividend of $38.00 per share.
Auto-generated from live market data. For educational purposes only — not financial advice.
Illustrative examples of common use cases, written by the DividendFlow team — not customer reviews.
Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.
I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.
Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.
As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.
The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.
For educational purposes only. Not financial advice.
Share your real experience on Trustpilot →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever